argus

Zydus Lifesciences Limited

NSE: ZYDUSLIFEINE010B010271,16,114 Cr

Timeline

Time (IST)TypeMEventSrc
04 Feb, 02:38 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated February 04, 2026, titled "Zydus receives tentative approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg".nse
31 Jan, 06:29 pmZydus Lifesciences Limited has informed the Exchange about change in Managementnse
31 Jan, 06:25 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Change in Managementbse
27 Jan, 04:42 pmZydus Lifesciences Ltd - 532321 - Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter / Nine Months Ended On December 31, 2025.bse
23 Jan, 05:45 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated January 23, 2026, titled "Outcome of USFDA inspection".nse
23 Jan, 05:42 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
22 Jan, 09:54 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
22 Jan, 09:51 amZydus Lifesciences Limited has informed the Exchange regarding a press release dated January 22, 2026, titled "Zydus launches the world s first biosimilar of Nivolumab, Tishtha , in India to treat multiple cancers".nse
20 Jan, 10:36 amZydus Lifesciences Limited has informed the Exchange regarding 'Revision in ESG Rating'.nse
17 Jan, 05:54 pmZydus Lifesciences Ltd - 532321 - Updatebse
17 Jan, 05:51 pmZydus Lifesciences Limited has informed the Exchange about General Updatesnse
15 Jan, 05:30 pmZydus Lifesciences Ltd - 532321 - Closing Of Acquisitionbse
15 Jan, 05:28 pmZydus Lifesciences Limited has informed the Exchange about General Updatesnse
15 Jan, 01:16 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated January 15, 2026, titled "Zydus receives final approval from USFDA for Eltrombopag Tablets,12.5 mg, 25 mg, 50 mg, and 75 mg".nse
15 Jan, 01:14 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
13 Jan, 10:04 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
13 Jan, 10:01 amZydus Lifesciences Limited has informed the Exchange regarding a press release dated January 13, 2026, titled "Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)".nse
10 Jan, 02:16 pmZydus Lifesciences Ltd - 532321 - Updatebse
10 Jan, 02:11 pmZydus Lifesciences Limited has informed the Exchange about General Updatesnse
02 Jan, 02:43 pmZydus Lifesciences Limited has informed the Exchange about General Updatesnse
30 Dec, 06:29 pmZydus Lifesciences Ltd - 532321 - Receipt Of Demand Order-In-Original From Assistant Commissioner Of State Tax, Gujaratbse
30 Dec, 06:25 pmZydus Lifesciences Limited has informed the Exchange about General Updatesnse
26 Dec, 07:12 pmZydus Lifesciences Limited has informed the Exchange regarding 'Intimation of ESG Rating'.nse
24 Dec, 05:57 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Updates on Acquisitionbse
24 Dec, 05:55 pmZydus Lifesciences Limited has informed the Exchange about General Updatesnse
23 Dec, 06:28 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
23 Dec, 06:28 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO®. BLA has been approved by the USFDA".nse
19 Dec, 09:52 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
19 Dec, 09:49 amZydus Lifesciences Limited has informed the Exchange regarding a press release dated December 19, 2025, titled "Zydus Lifesciences Limited signs an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India".nse
16 Dec, 05:22 pmZydus Lifesciences Ltd - 532321 - Intimation Of ESG Ratingbse
16 Dec, 05:19 pmZydus Lifesciences Limited has informed the Exchange about General Updatesnse
15 Dec, 06:30 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
15 Dec, 06:30 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated December 15, 2025, titled "Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 NDA Resubmission".nse
10 Dec, 10:18 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
10 Dec, 10:14 amZydus Lifesciences Limited has informed the Exchange regarding a press release dated December 10, 2025, titled "Zydus launches biosimilar Denosumab 120 mg SC protecting bone health in cancer patients".nse
09 Dec, 05:31 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
09 Dec, 05:30 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated December 09, 2025, titled "Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada".nse
04 Dec, 12:47 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
04 Dec, 12:45 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated December 04, 2025, titled "Zydus receives EIR for the injectable facility located at Jarod".nse
27 Nov, 04:31 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
27 Nov, 04:28 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated November 27, 2025, titled "Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg".nse
26 Nov, 12:27 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
26 Nov, 12:24 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated November 26, 2025, titled "Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market.".nse
25 Nov, 03:58 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
25 Nov, 03:54 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated November 25, 2025, titled "Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg".nse
25 Nov, 11:19 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
25 Nov, 11:16 amZydus Lifesciences Limited has informed the Exchange about Investor Presentationnse
19 Nov, 04:41 pmZydus Lifesciences Ltd - 532321 - General Updatebse
19 Nov, 04:36 pmZydus Lifesciences Limited has informed the Exchange about General Updatesnse
17 Nov, 06:58 pmZydus Lifesciences Limited has informed the Exchange regarding 'Disclosures under SEBI (Prohibition of Insider Trading) Regulations, 2015'.nse